Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Here, we report the development of an efficient gene editing therapy for GATA2 deficiency using prime editing with a favorable safety profile in terms of off-target effects and genotoxicity.
Appeared: Friday, October 2. Science Translational Medicine. Peer-reviewed journal.